This study reported the safety and effectiveness of a combination of carfilzomib (Kyprolis), bendamustine (Treanda), and dexamethasone (Decadron) for patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that a combination of carfilzomib, bendamustine, and dexamethasone (CBd) showed promising effectiveness in these patients. 

This study analyzed the effectiveness and safety of new hormonal therapies (nHTs) in patients with non-metastatic castration-resistant prostate cancer (CRPC). The authors concluded that nHT improved the outcomes of these patients. 

This study compared mecobalamin (vitamin B12) injections with mecobalamin tablets for the treatment of diabetic peripheral neuropathy (DPN; nerve damage). It showed that after 8 weeks of treatment, patients treated with mecobalamin injections showed signs of nerves being repaired, while no effects were seen in those taking the tablets.  

This study looked at tirzepatide, a new treatment for type 2 diabetes, compared to semaglutide (Ozempic).  It found that, depending on the dose, tirzepatide was similarly or more effective at controlling blood glucose than semaglutide. 

This review compared using two antiplatelet medications to aspirin (Bayer) alone following a stroke. It found that dual antiplatelet therapy (DAPT) reduced the risk of a second stroke, but led to more bleeding.

This study compared the outcomes of proteasome inhibitors (PIs) versus immunomodulators (IMs) as maintenance therapy for patients with newly diagnosed MM. The data showed that PIs maintenance increased the survival outcomes compared to IMs in these patients.

This study investigated the frequency and outcomes of contralateral axillary metastasis (CAM) in patients with inflammatory breast cancer (IBC). The data showed that CAM was common at diagnosis in patients with IBC and was best identified by ultrasound and positron emission tomography (PET).

This study compared the effectiveness and safety outcomes of atezolizumab (Tecentriq) alone or with chemotherapy (CT) for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). The data showed that atezolizumab alone might be a better treatment option than atezolizumab plus CT for these patients.

This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including chronic lymphocytic leukemia (CLL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial is being carried out at multiple sites across the United States. 

This article compared the safety and effectiveness of PD-L1/PD-1 immunotherapies (IT) for non-small cell lung cancer (NSCLC). The authors found that in the first-line setting, the most effective treatments for PD-L1 positive NSCLC were atezolizumab (Tecentriq), pembrolizumab (Keytruda)/chemotherapy (CT) combination, and nivolumab (Opdivo)/ipilimumab (Yervoy).